EGFR and lung adenocarcinoma: Reynolds et al. showed that NGS analysis could be successfully performed on residual cell pellets obtained from LBC samples of lung adenocarcinoma and that their gene hotspot panel was able to identify clinically relevant EGFR variants, as well as mutations in ERBB2, KRAS, MET, and PIK3CA [44].